Siegfried Holding, a Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, entered into a CHF 650 m term and revolving facilities agreement, with UBS Switzerland acting as mandated lead arranger, coordinator and agent. In
Homburger advised Siegfried Holding in connection with the bridge financing for the acquisition of three drug substances sites in the US and Australia. The context On May 1, 2026, Siegfried Holding, a globally active Contract Development and
Homburger advised Siegfried Holding in connection with the company’s issuance of CHF 300 m 1.3% bonds, to be listed on the SIX Swiss Exchange. Zürcher Kantonalbank and Commerzbank Aktiengesellschaft served as managers on
Siegfried Holding entered into a Swiss law governed Chf 300 million revolving credit facility agreement arranged by Zürcher Kantonalbank and Credit Suisse and syndicated among fourteen banks, mostly Swiss banks.
